【诺华(NVS.US)Q2业绩超预期,新药组合发力难抵可善挺失色与CFO变动冲击】瑞士制药巨头诺华(NVS.US)股价周

智通财经
17 Jul
【诺华(NVS.US)Q2业绩超预期,新药组合发力难抵可善挺失色与CFO变动冲击】瑞士制药巨头诺华(NVS.US)股价周四美股盘前出现波动,一度下跌1.3%,将今年以来的累计涨幅进一步收窄。此前公布的财报显示,核心产品可善挺(Cosentyx)销售表现未达预期,同时担任公司财务掌舵人十余年的哈里·基尔希宣布退休,为原本小幅上调的业绩预期增添变数。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10